Low-dose vemurafenib monotherapy in -mutated Erdheim-Chester disease.
作者信息
Ruan Gordon J, Hazim Antonious, Abeykoon Jithma P, Scheckel Caleb, Vassallo Robert, Ryu Jay H, Tobin W Oliver, Koster Matthew J, Bennani N Nora, Rech Karen L, Young Jason R, Shah Mithun V, Goyal Gaurav, Go Ronald S
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
出版信息
Leuk Lymphoma. 2020 Nov;61(11):2733-2737. doi: 10.1080/10428194.2020.1783447. Epub 2020 Jul 1.
Abstract
摘要
相似文献
1
Low-dose vemurafenib monotherapy in -mutated Erdheim-Chester disease.低剂量维莫非尼单药治疗BRAF突变的 Erdheim-Chester 病。
Leuk Lymphoma. 2020 Nov;61(11):2733-2737. doi: 10.1080/10428194.2020.1783447. Epub 2020 Jul 1.
2
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.BRAF(V600E) 突变型 Erdheim-Chester 病患者应用 vemurafenib 的可重现和持续疗效。
J Clin Oncol. 2015 Feb 10;33(5):411-8. doi: 10.1200/JCO.2014.57.1950. Epub 2014 Nov 24.
3
An effective treatment in Erdheim Chester disease: vemurafenib: a case report.厄德海姆-切斯特病的有效治疗：威罗非尼：一例报告。
J Med Case Rep. 2023 Oct 12;17(1):426. doi: 10.1186/s13256-023-04153-z.
4
A cytologic diagnosis of BRAF Erdheim-Chester disease on pericardial fluid.心包积液的BRAF型 Erdheim-Chester病的细胞学诊断。
Acta Clin Belg. 2017 Oct;72(5):369-371. doi: 10.1080/17843286.2017.1290861. Epub 2017 Feb 22.
5
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.携带 BRAF V600E 突变的多系统和难治性 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症中维莫非尼的显著疗效。
Blood. 2013 Feb 28;121(9):1495-500. doi: 10.1182/blood-2012-07-446286. Epub 2012 Dec 20.
6
Hypoalphalipoproteinemia and BRAF Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.低α脂蛋白血症和 BRAF 突变是 Erdheim-Chester 病主动脉浸润的主要预测因子。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.
7
Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.在 Erdheim-Chester 病中，低剂量维莫非尼联合阿那白滞素具有更高的疗效和耐受性：迈向联合靶向治疗和免疫治疗的范例
Acta Oncol. 2016 Jul;55(7):930-2. doi: 10.3109/0284186X.2015.1120885. Epub 2016 Mar 31.
8
The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.组织细胞增多症厄尔布-切斯特病是一种炎性髓系肿瘤。
Expert Rev Clin Immunol. 2015;11(9):1033-42. doi: 10.1586/1744666X.2015.1060857. Epub 2015 Jul 21.
9
[Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].维莫非尼治疗BRAF（V600E）突变型 Erdheim-Chester病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Sep 14;42(9):752-756. doi: 10.3760/cma.j.issn.0253-2727.2021.09.007.
10
Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.维莫非尼（BRAF抑制剂）治疗眼眶 Erdheim-Chester 病
Ophthalmic Plast Reconstr Surg. 2017 Nov/Dec;33(6):e138-e139. doi: 10.1097/IOP.0000000000000866.
引用本文的文献
1
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.荷兰和比利时组织细胞肿瘤患者靶向治疗的真实世界经验。
Blood Neoplasia. 2024 Jun 10;1(3):100023. doi: 10.1016/j.bneo.2024.100023. eCollection 2024 Sep.
2
Very low-dose vemurafenib maintenance for cardiac Erdheim Chester disease.极低剂量维莫非尼维持治疗心脏型 Erdheim-Chester 病
Blood Res. 2025 Apr 11;60(1):25. doi: 10.1007/s44313-025-00075-5.
3
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.免疫疗法和靶向疗法在癌症治疗中的潜在作用：当代护理实践
Heliyon. 2024 Jan 17;10(2):e24559. doi: 10.1016/j.heliyon.2024.e24559. eCollection 2024 Jan 30.
4
Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.双侧眼眶肿块伴多系统症状的 Erdheim-Chester 病：两例报告。
World J Surg Oncol. 2023 Jul 31;21(1):233. doi: 10.1186/s12957-023-03123-5.
本文引用的文献
1
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.骨硬化性嗜酸性肉芽肿：分子时代下的评估、诊断和治疗的共识建议。
Blood. 2020 May 28;135(22):1929-1945. doi: 10.1182/blood.2019003507.
2
Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.真实世界中 BRAF/MEK 抑制剂在 Erdheim-Chester 病患者中的毒性体验。
Oncologist. 2020 Feb;25(2):e386-e390. doi: 10.1634/theoncologist.2019-0606. Epub 2019 Nov 19.
3
Single-agent dabrafenib for -mutated histiocytosis.单药达拉非尼治疗 BRAF 突变型组织细胞增多症。 （你这里原文“-mutated”应该是有个具体基因名称没写全，我推测为BRAF ，你可根据实际情况调整）
Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22.
4
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.维莫非尼治疗 BRAF V600 突变型 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症：来自组织学独立、开放标签 VE-BASKET 研究的数据分析。
JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.
5
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).针对54例 Erdheim-Chester病患者的靶向治疗，包括中断治疗后的随访（LOVE研究）。
Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30.
6
Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. cladribine 治疗 Erdheim-Chester 病的临床和放射学反应。
JAMA Oncol. 2017 Sep 1;3(9):1253-1256. doi: 10.1001/jamaoncol.2017.0041.
7
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.转移性黑色素瘤患者 BRAF 和 MEK 抑制剂毒性的管理。
Ther Adv Med Oncol. 2015 Mar;7(2):122-36. doi: 10.1177/1758834014566428.
8
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.BRAF(V600E) 突变型 Erdheim-Chester 病患者应用 vemurafenib 的可重现和持续疗效。
J Clin Oncol. 2015 Feb 10;33(5):411-8. doi: 10.1200/JCO.2014.57.1950. Epub 2014 Nov 24.
Zotero 插件